论文部分内容阅读
ＦＤＡ肺部 /变态反应药物顾问委员会已经同意葛兰素史克 (ＧＳＫ)公司的丙酸氟替卡松 (ｆｌｕｔｉｃａｓｏｎｅ ,Ｆｌｏｖｅｎｔ)吸入粉末和丙酸氟替卡松 /沙美特罗 (Ａｄ ｖａｉｒ)吸入粉末治疗慢性阻塞性肺病 (ＣＯＰＤ)。两药在美国上市用以哮喘的维持治疗 ,Ａｄｖａｉｒ中
The FDA Lung / Allergy Advisory Board has approved GlaxoSmithKline’s fluticasone (Flovent) inhalation powder and fluticasone propionate / Ad vair inhalation powder for the treatment of chronic obstructive pulmonary disease COPD). Both drugs are marketed in the United States for the maintenance of asthma, Advair